Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is listed today as Trevi Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2022 | $55 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Oct 2021 | $3 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Oct 2021 | $12 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Jul 2017 | $52 M | No. 2 | $50 to $250 million | equity | SEC | |
| Dec 2012 | $7 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Trevi Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2022).
SEC Form D · Apr 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2022
That is all the official record says: Trevi Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Trevi Therapeutics, Inc. are on record.
Investors#
22 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Anne Vanlent | Person | not stated | not stated | Held Series A and C preferred stock, director (Form 3, 2019) | SEC Form 3 |
| Aperture Venture Partners IV, L.P. | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Aperture Ventures IV Management, LLC | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| David P. Meeker | Person | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2019) | SEC Form 3 |
| Debra A. Drake | Person | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Invest A/s Lundbeckfond | Person | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Jennifer L. Good | Person | not stated | not stated | Held Series A and C preferred stock, 10% owner, director (Form 3, 2019) | SEC Form 3 |
| Mellon Family Investment Co V | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Mfic V, LLC | Other | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Michael Thomas Heffernan | Person | not stated | not stated | Held Series C preferred stock, director (Form 3, 2019) | SEC Form 3 |
| Nea 16 GP, LLC | Other | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| NEA Partners 16, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| New Enterprise Associates 16, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Omega Fund V GP, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Omega Fund V GP Manager, Ltd. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Omega Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Peter F. Drake | Person | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Richard King Mellon Foundation | Other | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Thomas Sciascia | Person | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| TPG Group Holdings (SBS) Advisors, Inc. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| William J. Oshea | Person | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| William J. O'Shea | Person | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 18 investors.
Largest shareholders today
Institutions holding Trevi Therapeutics, Inc. shares, as of Sep 30, 2026.
- FMR LLC$195 M9.56%
- NEA Management Company, LLC$189 M9.27%
- BlackRock, Inc.$176 M8.62%
- Frazier Life Sciences Management, L.P.$137 M6.69%
- Wellington Management Group LLP$89 M4.37%
- Vanguard Capital Management LLC$88 M4.29%
- Vivo Capital, LLC$61 M2.97%
- Assenagon Asset Management S.A.$51 M2.47%
- State Street Corp$47 M2.30%
- Marshall Wace, LLP$45 M2.21%
- MPM Bioimpact LLC$43 M2.09%
- Geode Capital Management, LLC$42 M2.08%
- Soleus Capital Management, L.P.$39 M1.91%
- Eventide Asset Management, LLC$37 M1.79%
- Frontier Capital Management Co LLC$34 M1.68%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jennifer L. Good | Executive officer | Apr 2022 |
| Lisa L. Delfini | Executive officer | Apr 2022 |
| Thomas L. Sciascia | Executive officer | Apr 2022 |
| William L. Forbes | Executive officer | Apr 2022 |
| Chris Kirstine Seiter | Executive officer | Sep 2018 |
| Thomas R. Sciascia | Executive officer | Sep 2018 |
| Joseph R. Sorrentino | Executive officer | Dec 2012 |
| Anne L. VanLent | Director | Apr 2022 |
| David L. Meeker | Director | Apr 2022 |
| Dominick L. Colangelo | Director | Apr 2022 |
| Edward L. Mathers | Director | Apr 2022 |
| James L. Cassella | Director | Apr 2022 |
| Jennifer L. Good | Director | Apr 2022 |
| Michael L. Heffernan | Director | Apr 2022 |
| Annie L. Mitsak | Director | Sep 2018 |
| David R. Meeker | Director | Sep 2018 |
| Ed L. Mathers | Director | Sep 2018 |
| Eran L. Nadav | Director | Sep 2018 |
| Mette Kirstine Agger | Director | Sep 2018 |
| Cayce L. Denton | Director | Jul 2017 |
| Otello Kirstine Stampacchia | Director | Jul 2017 |
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.